Navigation Links
Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute
Date:5/14/2008

ncer and Phase 2 trials in metastatic colorectal and hormone-refractory prostate cancers, as well as a clinical trial of oral picoplatin in solid tumors. Picoplatin has not been approved by any regulatory authority for use in humans. For additional information please visit http://www.poniard.com.

This release contains forward-looking statements, including statements regarding Poniard's (the "Company's") business objectives and strategic goals, drug development plans, results of clinical trials and the potential safety and efficacy of its products in development. The Company's actual results may differ materially from those indicated in these forward-looking statements based on a number of factors, including risks and uncertainties associated with the Company's research and development activities; the results of pre- clinical and clinical testing; the receipt and timing of required regulatory approvals; the market's acceptance of the Company's proposed products; the Company's anticipated operating losses, need for future capital and ability to obtain future funding; competition from third parties; the Company's ability to preserve and protect intellectual property rights; the Company's dependence on third-party manufacturers and suppliers; the Company's lack of sales and marketing experience; the Company's ability to attract and retain key personnel; changes in technology, government regulation and general market conditions; and the risks and uncertainties described in the Company's current and periodic reports filed with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K for the year ended December 31, 2007 and the Company's Quarterly Report for the period ended March 31, 2008. Readers are cautioned not to place undue reliance on these forward- looking statements, which speak only as of the date of this release. The Company undertakes no obligation to update any f
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
2. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
5. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
6. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
7. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
8. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
9. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
10. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
11. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... SYDNEY and SOUTHAMPTON , ... -- Australian pharmaceutical company Pharmaxis Ltd (ASX: PXS) and UK biotechnology ... into a research collaboration to develop a selective inhibitor to ... fatal lung disease idiopathic pulmonary fibrosis (IPF). ... US. Current products are expected to produce global revenues in ...
(Date:8/4/2015)... VIEW, Calif. , Aug. 4, 2015  IRIDEX ... James H. Mackaness , who had served as chief ... since 2012, has resigned his positions with the Company, ... officer position at another company. Mr. Mackaness intends to ... Company,s second quarter earnings announcement and 10-Q filing. ...
(Date:8/4/2015)...   Regulus Therapeutics Inc . (NASDAQ: ... and development of innovative medicines targeting microRNAs, today ... ended June 30, 2015 and provided a summary ... second quarter of 2015 and recent period marked ... Paul Grint, M.D., President and CEO of Regulus. ...
Breaking Medicine Technology:Pharmaxis and Synairgen Announce Research Collaboration to Develop LOXL2 Inhibitor For Pulmonary Fibrosis 2Pharmaxis and Synairgen Announce Research Collaboration to Develop LOXL2 Inhibitor For Pulmonary Fibrosis 3IRIDEX Chief Financial Officer Resigns to Accept Another Opportunity 2Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 2Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 3Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 4Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 5Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 6Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 7Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 8Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 9Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 10
... Reaffirms Primacy and Safety of ,First Generation, Antisense, ... (Nasdaq: GNTA ) announced the presentation of ... lead anticancer,compound, can be safely administered in high ... data were presented by Dr. Anthony Tolcher, Director,of ...
... - Studies Show Improvement in Hemodynamics and Delay ... Actelion Pharmaceuticals US, Inc.,today announced positive results from ... and effective as a combination therapy,for the treatment ... suggest that Tracleer, when given in combination with ...
Cached Medicine Technology:Genasense(R) Can be Administered by Brief High-Dose IV Infusion 2Genasense(R) Can be Administered by Brief High-Dose IV Infusion 3Genasense(R) Can be Administered by Brief High-Dose IV Infusion 4Tracleer(R) Shows Clinical Benefit as Combination Therapy with Sildenafil for Pulmonary Arterial Hypertension 2Tracleer(R) Shows Clinical Benefit as Combination Therapy with Sildenafil for Pulmonary Arterial Hypertension 3
(Date:8/5/2015)... , ... August 05, 2015 , ... ... have just published updated guidelines for the management of malignant pleural mesothelioma. Details ... to read the article. , The updated guidelines issued by the European ...
(Date:8/5/2015)... ... August 05, 2015 , ... Friendly Smiles Dental ... practice; Dr. Daniel H. Huynh, DMD and Dr. Michael J. Foley, DMD. The full ... patients at all three location in the Tampa Bay area, where Friendly Smiles Dental ...
(Date:8/5/2015)... ... ... Social Security benefits are not keeping pace with rising household budgets, according ... Citizens League (TSCL). The record low growth in cost-of-living adjustments (COLAs) in recent ... age 65 and older, says TSCL. , When asked to select between four statements ...
(Date:8/5/2015)... ... , ... Stelari introduces their new collection, The Earth’s Song, inspired by the ... Earth’s Song. Combining fashion and activewear, Stelari’s new collection let’s you take your bohemian ... this collection is sure to make the spirit seeker swoon with prints as meaningful ...
(Date:8/5/2015)... ... ... A leader in Primary Care Continuing Medical Education (CME), Continuing Education ... as its new Director of Program Management. , Su has over 16 years experience ... Primary Care Network (PCN) as the Director, Program Implementation as well as Supervisor of ...
Breaking Medicine News(10 mins):Health News:New Mesothelioma Treatment Guidelines Issued By European Researchers, According to Surviving Mesothelioma 2Health News:Friendly Smiles Dental Care Welcomes New Doctors 2Health News:Majority of Older Americans Say Social Security Benefits Not Keeping up with Rising Household Costs, According to a New Survey from the Senior Citizens League 2Health News:Majority of Older Americans Say Social Security Benefits Not Keeping up with Rising Household Costs, According to a New Survey from the Senior Citizens League 3Health News:Stelari: Bohemian Chic Activewear Line 2Health News:Stelari: Bohemian Chic Activewear Line 3Health News:Leading Continuing Medical Education (CME) Provider, Continuing Education Company (CEC), hires expert Su Barnwell as Director of Program Management 2Health News:Leading Continuing Medical Education (CME) Provider, Continuing Education Company (CEC), hires expert Su Barnwell as Director of Program Management 3
... Cancer At All Stages Steps Away From Home, ... ... Medical University of,South Carolina (MUSC) Foundation for Research and Development announced ... for bladder cancer have shown to be accurate for only 40 ...
... of,National Problem Gambling Awareness Week, the state departments ... of counseling,and treatment services available to those affected ... not only the gambler but also their family,and ... Commonwealth,of Pennsylvania is committed to addressing compulsive gambling ...
... 10 Medco Health,Solutions, Inc. (NYSE: MHS ) ... follows:, On Monday, March 17, 2008, Timothy C. ... Inc., Medco,s specialty pharmacy,subsidiary, is scheduled to address the ... at the Boston Marriott Copley,Place will begin at 1:45 ...
... health insurance programs do not provide coverage to international ... ... Seven Corners, one of the,industry,s most experienced travel health insurance ... they,plan to travel abroad for spring break vacations. Most health insurance,programs ...
... be getting them, study says , , MONDAY, March 10 (HealthDay ... choices for kidney cancer more than clinical factors such as ... finds. , This means many patients who are candidates ... where only part of the kidney is removed, may not ...
... ZARS Pharma, Inc. announced,today the completion of ... promotion and distribution rights for all markets ... (lidocaine and tetracaine) Cream,7%/7%, a topical anesthetic ... patients undergoing potentially painful cosmetic and other,skin ...
Cached Medicine News:Health News:Cell Receptor on Track for Painless Bladder Cancer Test 2Health News:State Agencies Highlight Available Assistance During Problem Gambling Awareness Week 2Health News:Medco to Present at Cowen and Company and Lehman Brothers Health Care Conferences 2Health News:Seven Corners Alerts Spring Breakers that They Need Travel Insurance to Vacation Abroad 2Health News:Seven Corners Alerts Spring Breakers that They Need Travel Insurance to Vacation Abroad 3Health News:Surgeon's Preferences Dictate Choice of Kidney Cancer Surgery 2Health News:Surgeon's Preferences Dictate Choice of Kidney Cancer Surgery 3Health News:ZARS Pharma Announces Worldwide License Agreement With Galderma Pharma S.A. for Pliaglis(TM), a Topical Local Anesthetic 2Health News:ZARS Pharma Announces Worldwide License Agreement With Galderma Pharma S.A. for Pliaglis(TM), a Topical Local Anesthetic 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: